The It’s Your Yale website is now home to a new weekly e-newsletter, YourYale, for and about the staff; learn more about what to expect.
Jump to content
The Office of Sponsored Projects’ Clinical Agreements Team is authorized to negotiate and execute non-federal clinical trial agreements (CTAs) on behalf of Yale University, in accordance with University Policy 1104. The team provides a comprehensive and transparent approach to all activities related to industry-supported clinical trial agreements (CTAs). Specifically, the team’s responsibilities to assist in ensuring a timely initiation of industry-supported clinical trials at Yale, include, but are not limited to, the following:
The OSP process for setting up an industry-sponsored clinical trial should occur in parallel with the budget negotiations and the IRB approval process. View the details of this process on the clinical trial process flowchart.
Yale University and the Yale-New Haven Health System are affiliated entities with a long-standing relationship, and Yale University serves as the contracting entity for all clinical trial agreements. Together, they share the following common objectives regarding the conduct of clinical trials at Yale:
Please note: the Clinical Agreements team has the authority to execute (i.e., sign) clinical trial documentation (e.g., clinical trial agreements and confidential disclosure agreements (CDAs)) that legally binds Yale University. The Principal Investigator and other clinical trial investigators are not authorized to sign such documents on behalf of the University and may be asked only to read and acknowledge such documents.